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What oﬀers the best prediction of sustained virologic response
during combination therapy with interferon and ribavirin: Viral
dynamics, viral levels at certain time points, or a combination of both?q
Ola Weiland*
Department of Medicine, Division of Infectious Diseases, 173 Karolinska University Hospital Huddinge at Karolinska Institutet,
14186 Stockholm, SwedenSee Article, pages 21–28Methods to predict the ﬁnal outcome have been
sought and continuously reﬁned during the evolution
of standard of care (SOC) treatment for chronic hepati-
tis C virus (HCV) infection with interferon (IFN) and
ribavirin.
It was realised early on that genotype and viral load
were baseline factors of major importance for achieving
a ﬁnal sustained virologic response (SVR), and that
ribavirin was needed in combination with interferon to
improve the results [1]. In the pivotal studies evaluating
pegylated interferon and ribavirin treatment, it was
noted that genotypes 2 and 3 were ‘‘easy to treat” and
that patients with these genotypes responded much bet-
ter than patients with ‘‘diﬃcult to treat” genotypes 1
and 4 [2–4]. Thus, patients with the ‘‘easy to treat”
genotypes 2 and 3 responded with high SVR rates (over-
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A landmark study reﬁned the treatment length so that
SOC for genotype 2 and 3 was set at 24 weeks, whereas
genotypes 1 and 4 needed 48 weeks’ treatment [3]. In
addition to genotype, other baseline factors inﬂuence
the SVR rate, such as gender, extent of ﬁbrosis, age at
onset of the disease and race besides genotype and viral
load [2–4].
When the viral kinetics during treatment were stud-
ied, it was noted that the viral decline during initial
interferon treatment was much more pronounced for
genotypes 2 and 3 than for genotype 1 [5,6]. The viral
decline could be split into at least two phases with an ini-
tial very rapid 1st phase reduction during the ﬁrst days
of treatment reﬂecting a direct antiviral eﬀect of IFN.
The slower 2nd phase decline is considered to represent
the elimination of infected hepatocytes and typically
begins at day 3–4 [5,6]. It was also noted that the viral
decay was IFN dose-dependant and steeper with higher
doses. Overall, genotype 1 patients had a 1 log decline in
HCV RNA levels during the 1st phase, whereas geno-
type 2 and 3 infections had a 3 log decline, reﬂecting that
these genotypes are easier to treat.
The presently used time points utilized to decide
whether treatment should be stopped or continued are
treatment weeks 4, 12 and 24. They constitute the basis
for guidelines used for treatment of chronic HCV infec-
tion [7,8]. Patients with rapid viral response (RVR)
meaning HCV RNA negativity already by treatment
week 4 can be treated for a shorter-than-standard treat-
ment. This means 24 weeks for genotype 1 and 12-16Published by Elsevier B.V. All rights reserved.
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oﬀers nearly the same results as treatment lasting 48 and
24 weeks, respectively [9–14]. How long patients with
genotypes 2 or 3 who do not achieve RVR should be
treated is not well deﬁned, but patients who achieve
RVR will have higher SVR rates than those who do
not, also when treated with shorter-than-standard treat-
ment schedules irrespective of genotype [14–16]. For
genotype 1 infections which respond less favourably to
treatment, guidelines on when to stop treatment that
will not be successful are needed.
Today, a stopping rule is generally applied in patients
who fail to achieve early viral response (EVR), meaning
at least a 2 log drop of HCV RNA levels from baseline
treatment week 12. This is advocated since the negative
predictive value (NPV) is over 95% and very few
patients who continue treatment will achieve SVR [2].
Patients with EVR who have genotype 1 infection and
become HCV RNA negative for the ﬁrst time at treat-
ment week 24, so called slow viral response, will achieve
higher SVR rates if treatment is prolonged to 72 weeks
[17–19].
It is obvious that the earlier a patient becomes HCV
RNA negative during treatment the higher the likeli-
hood to achieve SVR [8]. In fact, the viral decline and
slope during the 2nd phase HCV RNA decline might
be used to predict response and calculate the time
needed for treatment to achieve SVR. A single standard
IFN dose can be used to calculate the likelihood of a
non-response: Jessner et al. measured the viral load
within 24 h after one dose of 5 or 10 MU interferon
alfa-2b in 29 consecutive patients with chronic HCV
infection caused by genotype 1. A 24 h viral load decline
of less than 70% of baseline after 5 MU interferon was
the best pre-treatment measure to identify non-respond-
ers (speciﬁcity 100%, n = 10, 95% CI 74-100, sensitivity
83% (15/18), 59–96) [20]. Furthermore, Drusano and
Preston calculated that a negative HCV RNA test in
serum for at least 36 weeks was needed to obtain SVR
with 90% probability during SOC treatment of genotype
1 infections [21]. This has been further reﬁned by Lindh
et al., who from data obtained in a pilot study, suggested
that the calculated HCV RNA slope can be used to
decide the length of SOC treatment that is needed to
obtain SVR [22]. These authors found a strong correla-
tion between the 2nd phase slope and SVR. Patients
with a slope steeper than 0.7 log units/week obtained
SVR in 95% and those with a slope between 0.35 and
0.7 log units/week in 64%, whereas patients with slopes
below 0.35 log units/week all became non-SVR patients
with SOC treatment [22].
In this issue of the Journal, Neumann et al. have uti-
lized the HCV RNA decline and HCV RNA levels at
diﬀerent time points during combination treatment with
albinterferon alfa-2b or peginterferon alfa-2a and riba-
virin to calculate the positive and negative predictivevalue of SVR with a linear exhaustive search algorithm
[23]. The authors claim that improved SVR prediction
was possible when both the HCV RNA reduction
(VD) and levels of HCV RNA (VL) treatment week 2
and 4 were used in this algorithm. For these calculations
they used the results from 368 patients (80%) treated per
protocol or treated until discontinuation due to non-
response in the four-armed study [23]. As expected, most
patients with a larger initial viral decline (VD) week 2
and 4 achieved SVR whereas those with low VD failed
to do so. The authors used an exhaustive search com-
puter program to identify the thresholds of VD and viral
load (VL) at weeks 0, 2, 4, 6, 8 and 12 and their
combinations.
Overall, the VL thresholds were better for NPV cal-
culations than VD, whereas the latter were better for a
positive prediction of SVR than VL.
The best NPV for SVR was obtained when VD and
VL data were combined. Hence, at treatment week 4,
a VL > 5.5 log10 IU/mL and VD < 2 log10 IU/mL pro-
vided a 100% NPV in all treatment arms.
Patients who the authors claimed to have rapid initial
viral response (RIVR) meaning VD >2 log10 IU/mL
treatment week 2 had a high PPV for SVR (88–97%)
comparable to ﬁgures found for RVR (a negative
HCV RNA treatment week 4) and included a larger
group at an earlier time point than RVR. By using the
less stringent threshold VD >3 log10 IU/mL at week 4,
a PPV of 88–94% was seen in one-third to half of the
number of patients.
To complicate the calculations further, the authors
used a sequential prediction algorithm from weeks 2, 4
and 12 and divided the response patterns into 4 catego-
ries: rapid initial virologic response, partial initial viro-
logic response, no initial virologic response and low
initial virologic response. Some 28–35% of the patients
could, however, not be properly classiﬁed and for these
patients assessment of complete EVR is still needed for
prediction of SVR.
Overall, the authors found that by integrating VD
and VL data obtained sequentially at weeks 2 and 4,
totally 65–72% of the patients in the four treatment arms
demonstrated high PPV or NPV. These patients could
be identiﬁed already by treatment week 4.
What are the implications of these ﬁndings? Are they
likely to be used on a daily basis for deciding when to
stop or continue treatment during SOC treatment for
chronic HCV infection? Probably not, since most clini-
cians would ﬁnd them too cumbersome and diﬃcult to
use. They do, however, indicate that VD and VL data
during the ﬁrst 4 weeks of treatment in patients with
genotype 1, particularly when combined, can be used
to categorize patients in diﬀerent response groups, and
indicate the possibility that a subgroup who have a very
small chance to respond to SOC during 48 weeks treat-
ment can stop treatment already at week 4. This is at an
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currently operating guidelines, and can save unnecessary
adverse events and costs for society [7,24]. This, how-
ever, needs to be conﬁrmed in a larger prospective study,
which is not likely to be performed since the addition of
STAT-C drugs to SOC treatment oﬀers a promise to
increase the RVR rates in genotype 1 from some 10–
15% of today to 80–100%, making shorter treatment
schedules possible [25].
A favourable outcome of treatment is, however, also
to a very large extent dependent on a good compliance
of the patients to the treatment length and to ribavirin
and peg-IFN doses given, as indicated by the 80/80/80
rule [26].
In summary, the results of the study by Neumann
et al. indicate that VD data can be used to calculate
PPV better than VL determinations at certain time
points, and that the combination of VD and VL data
can do this even better. These calculations, however,
are likely to be regarded as complicated and expensive
and not practical for the every day care of patients.
Calculations of the VD or the 2nd phase slope during
the initial 4 weeks of treatment might, however, oﬀer a
possibility to individualize the treatment duration for
genotype 1 patients, from the categorized 24, 48 or 72
weeks’ treatment used today based on RVR or EVR,
to more ﬂexible treatment periods spanning from 24 to
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